Deworming drug, levamisole, is being evaluated by the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) following concerns about its links with leukoencephalopathy.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results